Cutaneous T-Cell Lymphoma

A lymphoma is a type of cancer that is derived from white blood cells in circulating blood and in lymph nodes called lymphocytes .  These cells, known as B-cells and T-cells, play a major role in the body’s immune defense mechanisms against infections and cancer.  However, some lymphocytes may themselves undergo mutations and become malignant .

When the malignant lymphocytes accumulate in a solid organ such as the lymph nodes, liver, or spleen, the disease is called lymphoma.  When they are found predominantly in the circulating blood, the disease is considered  leukemia.  It is possible to have lymphoma and leukemia at the same time.

In the case of a lymphoma that starts with  lymphocytes that reside in the skin, almost always T-cells, the disease is called cutaneous, meaning skin, T-cell lymphoma.  The common abbreviation is CTCL.  Because the disease is rare, and has many different appearances in the skin, it can be very difficult to diagnose.

Stages  of  CTCL
Stage I or Patch Stage:  The earliest form of CTCL begins as pink to salmon-colored patches on the skin that are flat, dry, and flaky.  The rash may or may not be itchy.  It may look like eczema, psoriasis, or fungal infection of the skin.  Over time, it may gradually spread to more areas of the body and begin to itch.  You may hear older names still in use for this stage of CTCL such as “parapsoriasis” or “mycosis fungoides.”

Stage II or Plaque Stage:  As the patches spread and enlarge, they may also become elevated to form plaques.  Elevation is a sign of more advanced disease.  It is common for the rash to affect areas that are protected from the sun, such as the buttocks, groins, and female breasts.  Unlike the more common skin cancers, such as basal cell and squamous cell carcinomas, CTCL is actually helped by sunlight.

Stage III or Tumor Stage:  Tumors of CTCL are nodules or masses in the skin that are higher than they are wide and may break down into ulcers and get infected.  Tumors may arise from patches or plaques in a slow gradual progression, or they may arise abruptly from normal-appearing skin, indicating advanced disease.  These patients are more likely to also have solid organ involvement.

Stage IV or Erythroderma/Leukemic Stage: Erythroderma means that 90% or more of the skin surface is red and scaly, usually not elevated, and extremely itchy.  The erythrodermic rash may have developed over time from patches and plaques, or it may have started as erythroderma from the onset.  These patients are also more likely to have lymph node involvement and malignant T-cells circulating in their bloodstream.

Diagnosis of CTCL
Just as CTCL can be difficult to diagnose by examination because the disease mimics other common skin diseases, skin biopsies are often not definitive in the early stages.  The pathologist may report some abnormal T-cells in the skin and suspect early CTCL, but their quantity and degree of abnormality may not be sufficient to confirm the diagnosis.  Another test that can be run on the skin biopsy tissue is called gene analysis.  Because the malignant T-cells arose from mutations in their DNA, DNA analysis can show a difference between normal DNA and DNA in the cancer cells.  Unfortunately, this test is not very sensitive in early disease and leads to many false-negative results.

Any persistently enlarged or swollen lymph gland should be biopsied.  In erythrodermic  or Stage IV patients, the blood smear may show the larger malignant T-cells.  In addition, other T-cell immunologic markers and genes of  lymphocytes in the circulation can be studied to confirm the leukemic phase of CTCL.

Treatment of CTCL
The treatment of CTCL depends on the staging of the disease and whether there exists any internal involvement such as lymph nodes or blood in addition to the skin rash.   The disease is so unique and variable in its behavior that treatment must be tailored to each individual case.

In general, CTCL is considered incurable, but long-term remissions can be achieved with a variety of medicines, ultraviolet light treatments, and radiation, such that patients do not die from this disease.  Our goal then is to maintain remission or reduce activity of disease so that patients live a normal lifespan and die from other natural causes.

Here are some examples of how a patient may be treated at the different stages of CTCL.  As a dermatologist, the majority of the patients I see with CTCL have the patch/plaque rash.   If the skin involvement is limited to less than 10% of body surface area, I may try a potent topical steroid ointment or a chemotherapy gel called Targretin.  If the rash does not clear after a few months of treatment, or if it involves more than 10% of the body surface area, full body ultraviolet light therapy is delivered by an in-office narrow band UVB cabinet.  We can expect remission in 70-80% of such cases.

If the disease does not respond well to intensive narrow band UVB treatment given three times weekly for months, then we may select photochemotherapy, also known as PUVA, which is the combination of a pill called Psoralen plus UVA light in a full body cabinet.   A pill form of Targretin may also be prescribed.

If the skin shows CTCL tumor nodules, then we must consult our colleagues in the specialty of radiation oncology to give radiation therapy to the nodules and to scan the body for internal involvement.  Fortunately, the tumors are exquisitely sensitive to radiation and resolve relatively quickly.  If there is no internal involvement at this point, we can maintain that patient in remission with ultraviolet phototherapy.  If internal lymphoma is identified, then the medical oncologist may select certain pill or injectable chemotherapies.

If the skin shows erythroderma, that is, nearly total body red scaly itchy skin sometimes called exfoliative dermatitis, the dermatologist and oncologist will have to collaborate.  The skin-directed therapies such as topical steroids and ultraviolet light may improve the symptoms but do not help the lymph node or leukemia, a condition also known as the Sezary syndrome.  A combination of chemotherapy including alpha-interferon and a blood-cleansing treatment called photopheresis has been shown to improved quality of life and prolong life.  Stem cell transplantation for cure of Sezary syndrome is under study at MD Anderson Cancer Center.

Prognosis of CTCL
The prognosis of CTCL is directly correlated to the Stage at diagnosis.  It is also fair to say that the more extensive the skin involvement is, then the higher the risk of internal involvement.  Therefore, early Stage I and II patients have the best prognosis such that their lifespan may not be reduced at all by having the disease, while Stage III and IV patients statistically have the poorest survival measured in years after the diagnosis is made.

More About Skin Cancer:
When Should a Primary Care Doc Refer to a Dermatologist?
Two New Drugs for Metastatic Malignant Melanoma

Bookmark the permalink.

4 Responses to Cutaneous T-Cell Lymphoma

  1. Melody Galka says:

    Dr. Camisa, my daughter who is 34 just had a mole biopsyed on from her thigh. the Dr. said that it is a spitz nevi specifically junctional type arranged as nests, with architectural features for dysplastic nevus. Junctional poliferation of epitheleal malanocytes.
    Recommended re-excision of 3 mm of normal tissue. He wanted to do a punch biopsy but she is going to a “better” dermatologist who is mohs. what do you suggest?

    • DrCamisa says:

      In general, a conservative excision with a margin of 3-5mm is considered adequate for a dysplastic or Spitz nevus. It is not necessary and probably not recommended to treat these lesions with Mohs microscopically controlled surgery.

  2. Terri says:

    I was wondering. If a teen age female patient came in w/ red scaly rash which was t cell lymphoma, should it have been mistaken for psoriasis or a “funky immune system” for nearly 6 years before another dermatologist realized it was not psoraiasis, but cutaneous t cell lymphoma? Should this dermatologist be held accountable? By the time the second dermatologist confirmed t cell lymphoma (the first NEVER mentioned lymphoma in nearly 6 years of treating said teen), the lymphoma had spread to her organs resulting in the need for a stem cell transplant. An infection brought on by weak immune system turned into pneumonia/ARDS and eventually killed this 20 year old. Should this first dermatologist be held accountable? If he had diagnosed her in that 5 years he told us she had a “funky immune system” perhaps she wouldn’t have had a 10 pound tumor in her chest and other tumors in her pelvis and neck. Let me know, if you will. I currently have an attorney looking into the matter, but would love to hear someone else’s take on it.

    • DrCamisa says:

      Thank you for your letter and being upfront about pursuing litigation. I cannot speak to the specific case because I do not know all of the details, and I am not an expert witness. Please re-read the first paragraph under “Diagnosis of CTCL.” I stand by the information written there.

Leave a Reply

Your email address will not be published. Required fields are marked *